Clará MMG, Figueredo MJ, Sabatier, CA, Hernández, KC

Language: Spanish
References: 10
Page:
PDF size: 215.37 Kb.

ABSTRACT

Demyelinating Pseudotumor is a rare variant of Multiple Sclerosis (MS) characterized by beingan aggressive and rapidly progressive form, it can present as a single large lesion in the deep white substance and more rarely a second lesion reminiscent of multicentric gliomas. It usually leads to severe disabilityor death in week so months, without medical supervision. In patients who survive this disease, a recurrent form of Multiple Sclerosis is observed. A clinical case is described that presents demyelinating pseudotumor of 63 years of age, without a family history of suffering from the disease, with neurological deficit and little improvement after treatment with steroids.

REFERENCES

1. Medina A, Bú J, Ávila-De la Puente C, Medina-Escobar R, Gómez PM, García-Espinosa MO. Variante Atípica Aguda de Esclerosis Múltiple con Lesiones Pseudotumorales: Presentación de caso. Rev Archivos de Medicina. Tegucigalpa, Honduras, 2017; 13(4)6. Disponible en: http://www.archivosdemedicina.com/medicina-de-familia/variante-atiacutepica-aguda-de-esclerosis-muacuteltiple-con-lesiones- pseudotumorales-reporte-de-caso.pdf.

2. Núñez-Velasco S, Vargas-Sánchez A, Castañeda-Moreno V, Zúñiga Ramírez C, Ruiz-Sandoval JL. Presentación clínica, radiológica y patológica de las formas pseudotumorales de esclerosis múltiple. Rev Med Hipoc, 2011; 3: 6-8.

3. Mauri-Fábrega L, Díaz-Sánchez M, Casado-Chocán JL, Uclés-Sánchez AJ. Pseudotumoral forms of multiple sclerosis. Rev. Eur Neurol, 2014; 72: 72-78.

4. Turatti M, Gajofatto A, Bianchi MR, Ferrari S, Monaco S, et al. Benign course of tumour-like multiple sclerosis. Rev. J Neurol Sci, 2013; 324: 156-162.

5. Miller TR, Mohan S, Choudhri AF, Gandhi D, Jindal G. Advances in MultipleSclerosis and its Variants: Conventional and NewerImagingTechniques. Rev. Radiol Clin North Am, 2014;52:321-36.

6. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, et al.MRI in multiple sclerosis: current status and future prospects. Rev. Lancet Neurol.2008; 7:615-25.

7. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophyin multiple sclerosis. Rev. Lancet Neurol. 2006; 5:158-70.

8. Martinez-Altarriba MC, Ramos-Campoy O, Luna-Calcaño IM, ArrietaAntón E. Diagnóstico y tratamiento. Rev. Semergen, 2015; 41: 324-328.

9. Bunyan RF, Tang J, Weinshenker B. Acute demyelinatingdisorders: Emergencies and management. Rev. NeurolClin, 2012; 30: 285-307.

10. García-Domínguez JM, Guzmán VLJ. Catástrofes neurológicas por enfermedades desmielinizantes. Rev. Neurol, 2010; 25: 30-36.